- $560.14m
- -$88.48m
- $53.88m
- 48
- 38
- 15
- 24
Annual income statement for Kura Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 53.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 91.9 | 131 | 140 | 166 | 247 |
| Operating Profit | -91.9 | -131 | -140 | -166 | -193 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -89.6 | -130 | -136 | -153 | -172 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -89.6 | -130 | -136 | -153 | -174 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -89.6 | -130 | -136 | -153 | -174 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -89.6 | -130 | -136 | -153 | -174 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.69 | -1.96 | -2.03 | -2.08 | -2.02 |